undamentalytics Newsletter
Sign in

Intellia Therapeutics, Inc. revenue

Intellia Therapeutics, Inc.'s revenue was $67.7m in fiscal 2025, up 16.9% on the year before. Since fiscal 2016 ($16.5m) it has grown at a compound 17.0% a year. Over the last twelve months it was $59.5m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue1626304358335236586860
Growth on the year before—+58.5%+16.5%+41.6%+34.5%−43.0%+57.7%−30.4%+59.6%+16.9%—
Gross profit——30435833—————
Gross margin——100.0%100.0%100.0%100.0%—————

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Intellia Therapeutics, Inc. $59.5m 12.6% 3.9%
Fennec Pharmaceuticals Inc. $59.2m 77.8% 566.5%
Invivyd, Inc. $58.4m 26.3% —
Clinuvel Pharmaceuticals Ltd $64.3m 5.2% —
Nektar Therapeutics $54.6m -27.2% -14.6%
Tango Therapeutics, Inc. $53.8m 121.5% 16.9%

Compare with peers

Head to head: FENC vs NTLAIVVD vs NTLACUVL vs NTLA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Intellia Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Intellia Therapeutics, Inc.